Coya Therapeutics, Company Insiders
COYA Stock | 6.38 0.12 1.85% |
Coya Therapeutics,'s insiders are aggressively buying. The analysis of the overall insider sentiment regarding Coya Therapeutics, Common suggests that vertually all insiders are extremely bullish. Coya Therapeutics, employs about 8 people. The company is managed by 8 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive.
Coya Therapeutics,'s Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-11-14 | David S Snyder | Acquired 1800 @ 7.19 | View | ||
2024-11-11 | Fred Grossman | Acquired 2710 @ 7.37 | View |
Monitoring Coya Therapeutics,'s insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Coya |
Coya Therapeutics, Management Team Effectiveness
The company has return on total asset (ROA) of (0.2934) % which means that it has lost $0.2934 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5083) %, meaning that it created substantial loss on money invested by shareholders. Coya Therapeutics,'s management efficiency ratios could be used to measure how well Coya Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -0.2. In addition to that, Return On Capital Employed is expected to decline to -0.23. At present, Coya Therapeutics,'s Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 43.3 M, whereas Net Tangible Assets are projected to grow to (14.7 M).The current year's Common Stock Shares Outstanding is expected to grow to about 10.9 M, whereas Net Loss is projected to grow to (10.5 M).
Coya Therapeutics, Workforce Comparison
Coya Therapeutics, Common is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,404. Coya Therapeutics, maintains roughly 8.0 in number of employees contributing less than 1% to equities under Health Care industry.
Coya Therapeutics, Profit Margins
The company has Profit Margin (PM) of (1.12) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.17) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.17.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.8 | 0.9 |
|
|
Coya Therapeutics, Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coya Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coya Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Coya Therapeutics, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2023-03-01 | 18.0 | 18 | 1 | 489,979 | 0.00 |
Coya Therapeutics, Notable Stakeholders
A Coya Therapeutics, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Coya Therapeutics, often face trade-offs trying to please all of them. Coya Therapeutics,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Coya Therapeutics,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
FAPA DO | President Officer | Profile | |
David Snyder | CFO COO | Profile | |
Arun Swaminathan | Chief Officer | Profile | |
Howard Berman | Executive Chair | Profile | |
Gregory MacMichael | Chief Officer | Profile | |
Aaron Thome | Head Platform | Profile | |
Michelle Frazier | Senior Affairs | Profile | |
Karen MS | Senior Operations | Profile |
About Coya Therapeutics, Management Performance
The success or failure of an entity such as Coya Therapeutics, Common often depends on how effective the management is. Coya Therapeutics, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Coya management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Coya management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.19) | (0.20) | |
Return On Capital Employed | (0.22) | (0.23) | |
Return On Assets | (0.19) | (0.20) | |
Return On Equity | (0.22) | (0.21) |
Please note, the presentation of Coya Therapeutics,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Coya Therapeutics,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Coya Therapeutics,'s management manipulating its earnings.
Coya Therapeutics, Workforce Analysis
Traditionally, organizations such as Coya Therapeutics, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Coya Therapeutics, within its industry.Coya Therapeutics, Manpower Efficiency
Return on Coya Therapeutics, Manpower
Revenue Per Employee | 750.3K | |
Revenue Per Executive | 750.3K | |
Net Loss Per Employee | 998.5K | |
Net Loss Per Executive | 998.5K | |
Working Capital Per Employee | 4.5M | |
Working Capital Per Executive | 4.5M |
Complementary Tools for Coya Stock analysis
When running Coya Therapeutics,'s price analysis, check to measure Coya Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coya Therapeutics, is operating at the current time. Most of Coya Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Coya Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coya Therapeutics,'s price. Additionally, you may evaluate how the addition of Coya Therapeutics, to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |